Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.47 |
| ▸ | MAT2A | P31153 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.35 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.33 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.33 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.33 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101074 | 0.86 | PTGES (0.54) | PTGESPPARGPPARATEAD1TEAD4 | |
| SCHEMBL4089205 | 0.84 | PTGES (0.56) | PTGESPPARGPPARATEAD1TEAD4 | |
| SCHEMBL3582187 | 0.81 | PTGES (0.67) | PTGESPPARGPPARATEAD1TEAD4 | |
| SCHEMBL4097221 | 0.78 | PTGES (0.55) | PTGESPPARGTEAD1TEAD4TEAD2 | |
| SCHEMBL4097026 | 0.77 | PTGES (0.52) | PTGESPPARAPTPN11SCN9APTGDR | |
| SCHEMBL4090259 | 0.77 | PTGES (0.61) | PTGESPTPN11 | |
| SCHEMBL4923306 | 0.76 | PTGES (0.52) | PTGESSCN9A | |
| SCHEMBL4228522 | 0.76 | PTGES (0.59) | PTGESSCN9A | |
| SCHEMBL4090540 | 0.75 | DGAT1 (0.37) | PPARATEAD1SCN9A | |
| SCHEMBL4268491 | 0.74 | PTGES (0.60) | PTGESTEAD1TEAD4TEAD2TEAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | PYCR1, ARG2, ARG1 | PTGES 47/4885MAT2A 3174/4885PPARG 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.